P21 vs Survodutide
Side-by-side comparison of key properties, dosing, and research.
Cognitive EnhancementAnti-Aging & Longevity
P21GLP-1 / Weight Loss Agonists
Survodutide- Summary
- P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Half-Life
- Not well characterized; likely short, but neurogenic effects persist long after administration
- ~7 days
- Admin Route
- SubQ, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 100–500 mcg
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Frequency
- Once daily
- Once weekly
- Key Benefits
- Promotes hippocampal neurogenesis
- Enhances spatial memory and learning
- Increases BDNF expression
- Reduces amyloid-beta plaque formation (animal models)
- Anti-tau pathology potential
- Cognitive enhancement without stimulant effects
- Potential therapeutic for Alzheimer's and cognitive aging
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Side Effects
- Generally well tolerated in animal studies
- Limited human clinical data
- Injection site reactions
- Potential mild fatigue at initiation
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Stacks With
- —
- —